The acute reduction of low-density lipoprotein (LDL) cholesterol obtained by LDL-apheresis allows the role of the high level of circulating LDL on lipoprotein metabolism in heterozygous familial hypercholesterolemia (heterozygous FH) to be addressed. We studied apolipoprotein B (apoB) kinetics in five heterozygous FH patients before and the day after an apheresis treatment using endogenous labeling with [ 2 H 3 ]leucine. Compared with younger control subjects, heterozygous FH patients before apheresis showed a significant decrease in the fractional catabolic rate of LDL (0.24 Ϯ 0.08 vs. 0.65 Ϯ 0.22 day Ϫ1 ; P Ͻ 0.01), and LDL production was increased in heterozygous FH patients (18.9 Ϯ 7.0 vs. 9.9 Ϯ 4.2 mg/kg⅐day; P Ͻ 0.05). The modeling of postapheresis apoB kinetics was performed using a nonsteady state condition, taking into account the changing pool size of very low density lipoprotein (VLDL), intermediate density lipoprotein, and LDL apoB. The postapheresis kinetic parameters did not show statistical differences compared with preapheresis parameters in heterozygous FH patients; however, a trend for increases in fractional catabolic rate of LDL (0.24 Ϯ 0.08 vs. 0.35 Ϯ 0.09 day Ϫ1 ; P ϭ 0.067) and the production of VLDL (13.7 Ϯ 8.3 vs. 21.9 Ϯ 1.6 mg/ kg⅐day; P ϭ 0.076) was observed. These results suggested that the marked decrease in plasma LDL obtained a short time after LDLapheresis is able to stimulate LDL receptor activity and VLDL production in heterozygous FH. (J Clin Endocrinol Metab 86: 1679 -1686, 2001) H ETEROZYGOUS FAMILIAL hypercholesterolemia (heterozygous FH) is characterized by a genetic deficiency of the low-density lipoprotein (LDL) receptor. The high plasma LDL level observed in heterozygous FH patients was found to be the result of both decreased clearance and increased production of LDL (1, 2). The decreased fractional catabolic rate (FCR) of LDL is explained by the LDL receptor deficiency, whereas the mechanism responsible for increased LDL production is still unknown. This LDL overproduction has been shown to be the consequence of increased conversion of VLDL to LDL or a direct production of LDL (2-6). The high circulating LDL pool of heterozygous FH could lead, in addition to the preexisting genetic deficiency of LDL receptor, to down-regulation and inhibition of receptor activity (2, 7). Therefore, the high LDL production rate in heterozygous FH patients may substantially contribute to the observed decrease in the LDL FCR. This overproduction may also explain to some extent the inefficiency of lipid-lowering treatments in stimulating LDL receptor (LDL-R) activity in some heterozygous FH patients.
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H ETEROZYGOUS FAMILIAL hypercholesterolemia
(heterozygous FH) is characterized by a genetic deficiency of the low-density lipoprotein (LDL) receptor. The high plasma LDL level observed in heterozygous FH patients was found to be the result of both decreased clearance and increased production of LDL (1, 2) . The decreased fractional catabolic rate (FCR) of LDL is explained by the LDL receptor deficiency, whereas the mechanism responsible for increased LDL production is still unknown. This LDL overproduction has been shown to be the consequence of increased conversion of VLDL to LDL or a direct production of LDL (2) (3) (4) (5) (6) . The high circulating LDL pool of heterozygous FH could lead, in addition to the preexisting genetic deficiency of LDL receptor, to down-regulation and inhibition of receptor activity (2, 7) . Therefore, the high LDL production rate in heterozygous FH patients may substantially contribute to the observed decrease in the LDL FCR. This overproduction may also explain to some extent the inefficiency of lipid-lowering treatments in stimulating LDL receptor (LDL-R) activity in some heterozygous FH patients.
Cholesterol-lowering drugs (i.e. HMGCoA reductase inhibitors, bile acid sequestrant) have been effective in most heterozygous FH patients. An additional treatment is the use of LDL-apheresis, consisting of the extracorporeal removal of LDL. This intervention results in a marked reduction of plasma cholesterol, which returns to baseline after several days (8 -10) . This treatment is useful for patients who do not respond to drug therapy and may also be a good tool to determine the effect of the large pool size of LDL on the metabolic disturbances found in FH patients.
Kinetic studies performed 5-7 days after LDL-apheresis did not alter the kinetics of apolipoprotein B (apoB)-containing lipoproteins using exogenous (11) or endogenous (12, 13) labeling. These data suggested that the reduction of the plasma LDL pool size did not change apoB metabolism in either heterozygous FH patients (13) or normolipidemic subjects (12) in the long term. However, these kinetic studies were undertaken 1 week after apheresis, when the circulating LDL level had almost returned to baseline. Studies undertaken 1 day after apheresis showed that cholesterol synthesis is stimulated by apheresis (14, 15) , suggesting that apheresis could affect apoB metabolism for a very short time period. Only two kinetic studies were performed immediately after apheresis when the apoB and cholesterol levels were significantly decreased compared with baseline levels. In normolipidemic subjects an increased FCR of LDL was found 2 days after apheresis (12) . No change in the production rate of VLDL and LDL was observed; however, the nonsteady state of the LDL-apoB pool size was not taken into account in the modeling procedure. In another kinetic study undertaken in heterozygous FH, immediately after apheresis (16), the LDL FCR was significantly increased, with no change in apoB production; however, no information was given about the model used for the data analysis. In addition, a recent study showed that the LDL-apoB level rebound after apheresis cannot be fitted using unchanged LDL-apoB kinetic parameters (17) . The researchers suggested that LDL-apheresis may affect LDL-apoB kinetics. Thus, an important question remains unsolved. Is LDL-apheresis able to induce a change in the apoB kinetics of FH patients over a short time period?
In the present study we examined the kinetics of apoBcontaining lipoproteins in heterozygous FH patients before and the day after apheresis, when the LDL plasma level was still markedly decreased. These conditions allowed dissection of the role of the receptor defect from the role of the increased LDL pool on apoB metabolism in heterozygous FH. After apheresis we found a tendency for increases in VLDL production and LDL catabolism compared with basal values, whereas direct LDL production decreased.
Subjects and Methods Subjects
Five heterozygous FH patients (three men and two women, 53 Ϯ 9 yr old) and five normolipidemic subjects (all men; 24 Ϯ 2 yr old) participated in the study. The characteristics of patients and controls are shown in Table 1 .
All patients were resistant to lipid-lowering treatment and were included in LDL-apheresis treatment. The first kinetic study was performed on FH patients before they started LDL-apheresis treatment. None had been treated for at least 3 weeks before the first kinetic study (preapheresis kinetic study). None was treated with probucol. A second kinetic study (postapheresis study) was performed after three apheresis treatments performed every 2 weeks. LDL was removed from plasma by dextran sulfate-cellulose columns (Liposorber LA 15 TM, Kanegafuchi, Osaka, Japan). The postapheresis kinetic study was performed the day after the third apheresis. No lipid-lowering drug was administrated between each apheresis during the course of the study.
A kinetic study was performed on control subjects to determine control values of apoB kinetics. These subjects were not subjected to apheresis. Informed consent was obtained before the study, according to protocols approved by the ethical committee of the University Hospital of Nantes Medical School.
Kinetic study procedure
Subjects were instructed to consume a diet containing 50% of the daily caloric intake as carbohydrate, 35% as fat, and 15% as protein for at least 1 week before the study. [ 2 H 3 ]Leucine (99.8% enrichment; Mass Trace, Woburn, MA) was dissolved in a saline solution and tested for pyrogenicity and sterility before the study. After a 12-h fast a priming dose of 10 mol/kg [ 2 H 3 ]leucine was administered, immediately followed by a constant infusion of 10 mol/kg⅐h over a period of 14 h. The subjects fasted during the entire procedure. Venous blood samples were withdrawn in ethylenediamine tetraacetate tubes (Venoject, France) at baseline, every 15 min during the first hour, then every 30 min during the following 2 h, and finally hourly through the end of the isotope infusion. Plasma was separated by centrifugation for 30 min at 4 C. Sodium azide and gentamicin were added to each plasma sample to final concentrations of 0.05% and 0.005%, respectively.
Analytical procedures
Very low density lipoprotein (VLDL; density, Ͻ1.006 kg/L), intermediate density lipoprotein (IDL; density, 1.006 -1.019 kg/L), and LDL (density, 1.019 -1.063 kg/L) were isolated from 3-4 mL plasma by sequential ultracentrifugation using standard methods (18) with a fixed angle rotor at 40,000 rpm for 22 h at 10 C (Himac CP70, Hitachi, Hialeah, FL). Apolipoproteins of the lipoprotein fraction were concentrated (19) , and apoB100 was isolated from other apolipoproteins by SDS-PAGE using a discontinuous gel gradient (4%, 5%, and 10%). Apolipoproteins were identified by comparing migration distances to known molecular weight standards. Apolipoprotein bands were excised from polyacrylamide gels dried in vacuo for 2-3 h (RC 10 -10, Jouan, Saint Herblain, France). The desiccated gel slices were hydrolyzed with 1 mL 4 mol/L HCl (Sigma, St. Quentin Fallavier, France) at 110 C for 24 h.
Hydrolysates were evaporated to dryness, and the amino acids were purified by cation exchange chromatography using a Temex 50W-X8 resin (Bio-Rad Laboratories, Inc., Hercules, CA). Amino acids were derivatized using heptafluorobutyric anhydride (Fluka, Switzerland) before analysis by electron impact gas chromatography-mass spectrometry (5891A gas chromatograph connected with a 5971A quadrupole mass spectrometer, Hewlett-Packard Co., Palo Alto, CA). The procedures for chromatographic separations and mass spectrometric analyses of leucine were performed as previously described (20) . Isotopic abundance was reported as the tracer to tracee mass ratio (21) . ApoB concentrations were obtained in lipoprotein fractions using the isopropanol precipitation method (22) . The leucine content in precipitated apoB was determined using norleucine as the internal standard. A constant amount of norleucine (6 mol) was added to precipitated apoB, and the same procedure for hydrolysis, cation exchange chromatography, and derivatization (described above) was undertaken. In mass spectrometry, the ratio of leucine ion abundance to norleucine ion abundance was used to determine the quantity of leucine in the sample by comparison to a standard curve containing different amounts of leucine (0 -200 mol) and a constant amount of norleucine (6 mol). The corresponding amount of apoB was then calculated according to the number of leucine molecules per apoB molecule (23, 24) . The comparison of this internal standard method to the Lowry method (25) for apoB measurement has shown a linear regression slope of 1.1 (r 2 ϭ 0.98) on 10 samples of LDL-apoB. The VLDL-, IDL-, and LDL-apoB pool sizes were determined at three to five different times during the kinetic study before apheresis and at all time points during the postapheresis kinetic study.
For the control subjects, apoB concentrations were measured in lipoprotein fractions by immunonephelometry (Behring, Paris, France). Cholesterol and triglycerides were measured using commercially available enzymatic kits (Roche Molecular Biochemicals, Mannheim, Germany). The pool size of apoB (milligrams per kg) was calculated by multiplying the apoB plasma concentration (milligrams per L) in each fraction by 0.045 (plasma volume equal to 4.5% body weight).
Modeling
ApoB leucine tracer to tracee ratios in VLDL, IDL, and LDL were analyzed by multicompartmental modeling. The model used was a minimal compartmental model for apoB metabolism (Fig. 1) . In our experimental conditions a more complex compartmental model, previously used with data obtained for a longer time experiment (26) , did not provide a statistically better fit of tracer to tracee ratio data (27) . Our model included a precursor pool (compartment 1) from which apoB enters the VLDL compartment (compartment 10), IDL compartment (compartment 20), or LDL compartment (compartment 30) after a delay compartment (compartment 2). VLDL-apoB is converted into IDL-apoB or directly into LDL-apoB. ApoB can be removed from any compartment. Our model can estimate 1) the FCR of VLDL as the sum of the rate constants of conversion of VLDL into IDL and LDL and direct removal of VLDL; 2) the FCR of IDL as the sum of rate constants of IDL conversion into LDL and direct removal of IDL, and 3) the FCR of LDL as the rate constant of e removal of LDL from plasma. Compared with our previously published model developed using the same experimental conditions (27, 28) , direct input of IDL-apoB and LDL-apoB was added. The direct conversion process of VLDL-apoB into LDL-apoB was added to fit some patient data. The introduction of this shunt pathway for control subjects resulted in multiple solutions for the model; therefore, the shunt pathway process was not included for controls. The SAAM-II program (29) was used to determine the parameters of the model. The plasma free leucine tracer to tracee ratios were used as a forcing function describing the tracer to tracee ratios of the precursor pool (compartment 1) during the course of the infusion. The forcing function was created in SAAM-II, by linear interpolation between sequential data of plasma leucine tracer to tracee ratios. During the preapheresis kinetic study, we assumed that each subject remained in the steady state condition regarding transfer coefficients and apoB pool sizes in each compartment. The apoB production rate in milligrams per kg/day was calculated as the product of FCR and the pool size of apoB in the lipoprotein fraction. For the postapheresis kinetic study, the model had to take into account the nonsteady state of tracee mass (apoB pool size) of VLDL, IDL, and especially LDL, which was increasing during the 14-h study. The nonsteady state condition was modeled using two experiments in the SAAM-II program of the model shown in Fig. 1 . One experiment (tracer experiment) corresponded to the time course of tracer in each compartment, and the second experiment (tracee experiment) represented the time course of apoB (tracee) in each compartment. The tracer to tracee ratio data provided the link between these two experiments; the tracer experiment provided the numerator of the ratio, and the tracee experiment provided the denominator of the ratio. The tracee experiment was also associated with the VLDL-, IDL-, and LDL-apoB concentrations measured during the study.
Statistical analysis
Data are expressed as the mean Ϯ sd unless otherwise stated. Paired Student's t test was used for comparison of data obtained before and after the apheresis kinetic study. Unpaired Student's t test was used to compare the data for control subjects with the data for patients. The correlation between the change in LDL cholesterol and the LDL FCR was examined by linear regression analysis. P Յ 0.05 was considered significant. Table 1 , apheresis treatment decreased the concentrations of plasma cholesterol and LDL cholesterol in the five patients (65 Ϯ 6% and 77 Ϯ 5%, respectively). In the postapheresis kinetic study, the plasma and LDL cholesterol concentrations were not significantly different between patients and controls. The plasma triglyceride concentration of patients was significantly higher than that of controls and was not different in the two kinetic studies. ApoB concentrations obtained pre-and postapheresis kinetic studies for patients and controls are shown in Table 2 . The VLDL-apoB concentration of patients did not change significantly between the pre-and postapheresis kinetic studies and was not statistically different from the control value. The IDL-apoB concentration of patients was significantly higher than the control value and was significantly decreased in the postapheresis kinetic study, with no significant difference between patients and controls. The LDL-apoB concentration of patients was significantly higher than the control value and was significantly decreased in the postapheresis kinetic study, but remained significantly higher than the control value. In the postapheresis kinetic study, VLDL-apoB and IDL-apoB reached a steady state, whereas LDL-apoB was increasing during the entire study period (Fig. 2) .
Results

As shown in
The tracer to tracee ratio curves in VLDL-, IDL-, and LDLapoB in the pre-and postapheresis kinetic studies are shown in Fig. 3 for one patient, and apoB turnover rates calculated for each model pathway are shown in Fig. 1 . Kinetic parameters calculated for patients in the pre-and postapheresis kinetic studies and in control subjects are shown in Table 3 . In the preapheresis study a significant decrease in the FCRs of VLDL, IDL, and LDL and a significant increase in LDL production were observed in patients compared with controls. The increased LDL production was mainly due to a high direct LDL production in patients compared with controls (9.2 Ϯ 7.8 vs. 1.4 Ϯ 1.2 mg/kg⅐day; P ϭ 0.057). For heterozygous FH patients, VLDL and LDL direct production accounted for 51 Ϯ 7% and 33 Ϯ 15% of the total apoB production, respectively, whereas in controls the corresponding values were 80 Ϯ 7% and 8 Ϯ 7% (P Ͻ 0.01). No statistical differences were found between kinetic parameters obtained before and after apheresis, as indicated by paired t test. However, there was a trend for an increase in the FCR of LDL induced by apheresis that was correlated with the decrease in LDL cholesterol (r 2 ϭ 0.76; P Ͻ 0.05), indicating that the more LDL cholesterol decreases the more the FCR of LDL increases. There was also a trend for an increase in the production of VLDL-apoB (Table 3) in the postapheresis study compared with the preapheresis study, resulting in a significant increase in the fraction of VLDLapoB synthesis of the total apoB synthesis (76 Ϯ 13 vs. 51 Ϯ 7%; P Ͻ 0.05).
Discussion
We studied apoB metabolism of heterozygous FH patients before and 24 h after apheresis when LDL cholesterol was still markedly reduced compared with the baseline value. Before apheresis, heterozygous FH patients had decreased LDL FCR and increased LDL production compared with younger control subjects. The postapheresis kinetic study showed no statistical difference in apoB kinetic parameters compared with those in the preapheresis kinetic study. However, there was a trend for an increase in LDL FCR as well as in the production of VLDL. All five patients had an increased LDL FCR after apheresis compared before apheresis, and four of the five patients had an increased VLDL production rate. The inherent heterogeneity within patients associated with a small number of studied patients gave borderline P values.
A previous kinetic study performed 7 days after apheresis in heterozygous FH patients did not show any difference in the production rate or FCR of apoB-containing lipoproteins (13) . The apoB kinetic experiment was performed when the plasma LDL cholesterol level was close to baseline. These data demonstrated that apheresis treatment did not induce a long-term effect on apoB kinetics in heterozygous FH patients.
To dissect out the metabolic perturbations related to the LDL-R genetic deficiency from the perturbations secondary to the elevated LDL plasma level, we performed our kinetic study on the day immediately after the apheresis procedure to study its short-term effect and assess the lipoprotein metabolism changes in an acute LDL cholesterol reduction. These specific experimental settings allowed characterization of the apoB metabolism of heterozygous FH patients in the absence of a large LDL pool size. A nonsteady state modeling procedure was required to take into account the change in apoB pool size during the postapheresis study. We used a short-term protocol consisting of an 14-h infusion of tracer and assumed that there were linear turnover rates during the study period. This approach is supported by a recent study that demonstrated that the endogenous labeling method could detect changes in LDL FCR when undertaken as soon as possible after the apheresis procedure (9) .
Before apheresis, the FCR of LDL was decreased by about 60% in patients compared with controls. The values we found are similar to those in heterozygous FH patients using exogenous (see Ref. 1 for review) or endogenous labeling (6, 13) . This is consistent with a LDL-R defect. After the apheresis we observed a 45% increase in the LDL FCR of patients. These results suggested that despite the genetic defect, LDL-R activity could be stimulated in heterozygous FH patients. The apheresis treatment dramatically diminished LDL cholesterol and, therefore, the net cholesterol uptake by the liver. Apheresis thus may stimulate LDL-R synthesis by a decrease in the stored cholesterol within the cell (30) . This improvement in FCR may represent a reversible part of the defect in LDL catabolism in heterozygous FH.
Our data show that heterozygous FH patients have increased LDL production compared with controls. An increased plasma LDL level in heterozygous FH patients is related to both a low LDL FCR and a high LDL production (se Ref. 2 for review) . Assessment of the respective contributions of VLDL conversion and direct LDL production to the total LDL overproduction is not simple and requires the use of multicompartmental modeling to include the VLDL, IDL, and LDL in an integrated model. The conversion of VLDL to LDL was determined by the injection of radiolabeled VLDL and a multicompartmental approach in which the mass of LDL that was not accounted for by VLDL conversion was attributed to direct LDL production (3) (4) (5) . Endogenous labeling is a more direct method to assess direct LDL production, because the early part of the LDL tracer to tracee ratio curve can be analyzed. Using this method, the direct production of IDL and LDL was directly measured in normolidemic subjects (31, 32) and was markedly increased in heterozygous FH (6) . The use of a very rapid turnover pool of VLDL directly converted to LDL was also reported (13) . However, this latter option provided very high turnover rates of the VLDL shunt pathway, which do not correlate to physiological processes (32, 33) . Despite the fact that our model includes a direct conversion of VLDL to LDL, direct LDL production is required to fit the LDL tracer to tracee curve and the steady state mass of LDL. Our data show that about 50% of FH patient LDL synthesis comes from direct production, whereas it is about 10% for controls. The overproduction of LDL resulting from increased direct LDL production may play an important role in the atherogenesis of heterozygous FH by increasing the amount of circulating LDL with an increased retention time in plasma due to the receptor defect. This direct LDL production was not directly demonstrated in humans, but data support the direct LDL production pathway. Cultured hepatocytes synthesized LDL (23, 34 -36) , and these in vitro data suggested that hepatocytes may have the in vivo ability to secrete LDL. In vivo data in guinea pigs suggested that direct production of LDL could be decreased by statins (37) . Direct LDL production in heterozygous FH may be the result of a high cholesterol content in the liver, which may secrete LDL density particles (2, 5, 6, 38) . Despite the LDL-R genetic deficiency, the absolute flux of cholesterol entering the liver of FH patients is higher than that in normolipidemic subjects because of the large pool size of circulating LDL (2, 7, 39) . Thus, the decrease in cholesterol content in the liver after apheresis could explain the reduction of LDL direct production observed in three of the five FH patients. to the tracer to tracee ratio for VLDLapoB (f), IDL-apoB (ࡗ), and LDL-apoB (F), using a three-compartment model (see Fig. 1 We observed a 57% increase in VLDL production induced by apheresis in heterozygous FH patients. The elevated endogenous synthesis of cholesterol after apheresis (14, 40, 41) may be involved in the increased VLDL production. A correlation between VLDL production and cholesterol synthesis previously found in normolipidemic (42) and hyperlipidemic (43) subjects suggests that in heterozygous FH patients the liver may produce more VLDL-apoB in response to cholesterol synthesis stimulation. The VLDL production rate may be partly dependent on endogenous cholesterol synthesis that has been stimulated by apheresis. Apheresis changed the balance between these two distinct hepatic cholesterol pools, resulting in a coordinate change in the pattern of apoB secretion.
Statins are poorly effective in some heterozygous FH patients (8) . We postulate that this treatment failed in these patients because of the high direct LDL production that increased the hepatic cholesterol content and subsequently down-regulated LDL-R activity (7, 39) , preventing the effect of HMGCoA reductase inhibitors. These data support the hypothesis that in heterozygous FH, LDLR activity is substantially regulated by hepatic cholesterol content (2) . On the other hand, LDL-apheresis, by the marked plasma LDL removal, is able to stimulate LDL-R activity as well as endogenous cholesterol synthesis. The increased production rate of VLDL observed after apheresis is probably a key factor in the fast relapse of the patients secondary to these combined effects. Furthermore, our data suggested a key role played by the increased LDL production in the pathophysiology of heterozygous FH enhancing the genetic deficiency of LDL-R. It would be of interest to study statin-treated patients to determine whether the drug can offset the increase in VLDLapoB production following apheresis. These findings pointed out the relevance of the development of apoB production-lowering drugs in heterozygous FH, such as microsomal triglyceride transfer protein inhibitors targeting VLDL as well as direct LDL production. 
